scholarly journals Prevalence of impaired fasting glucose in different grades of obesity

2019 ◽  
Vol 6 (6) ◽  
pp. 1736
Author(s):  
Jitendra Kumar Rai ◽  
J. L. Wadhwani ◽  
Manuj Sharma ◽  
T. N. Dubey
Keyword(s):  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Age Group ◽  
Medical College ◽  
Obese Subjects ◽  
Gandhi Medical College

Background: Impaired fasting glucose (IFG) is a pre-stage to type 2 diabetes mellitus (T2DM) in adults and generally in obese population. In different studies this occurrence varied significantly, but the true prevalence is unknown due to lack of larger representative cohort studies. Authors objectives was to study the prevalence of IFG in different grades of obesity.Methods: One hundred obese subjects of obesity Grade1 (BMI >25 kg/m2 but <30) and Grade 2 (BMI >30 kg/m2) were studied at Gandhi Medical College, Bhopal from April 2019 to June 2019. Physical examination, blood investigations including fasting blood glucose and oral glucose tolerance test (OGTT) was carried out for all the patients.Results: Out of 100 subjects, 18(9%) males and 18(9%) females had IFG. Among male subjects highest IFG was recorded in the age group of 60+ years and in the weight rage of 71 to 80 kg. In female subjects, highest prevalence was in the age group 51 to 60 years and in weight range of 51-60 kg. Out of 24 males and 34 female of with Grade 1 obesity, 7% and 10.4% had IFG similarly, out of 25 males and 17 females with grade 2 obesity, 11% and 7.6% had IFG.Conclusions: IFG is highly prevalent in different grades of obesity. Obesity is the risk factor for the development of diabetes.

scholarly journals Prevalence of impaired glucose tolerance in different grades of obesity

2019 ◽  
Vol 6 (5) ◽  
pp. 1520
Author(s):  
Jitendra Kumar Rai ◽  
J. L. Wadhwani ◽  
Manuj Sharma ◽  
T. N. Dubey
Keyword(s):  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Obese People ◽  
Medical College ◽  
Complete Physical Examination ◽  
Obese Subjects ◽  
Gandhi Medical College

Background: Surgical Background: Impaired glucose tolerance is known precursor of type-2 diabetes mellitus and more prevalent in obese people, different studies have varied results and true prevalence is still debatable. Aims of this study  to investigate the prevalence of IGT in different grades of obesity.Methods: Authors have studied100 patients with obesity Grade1 (BMI >25 kg/m2 but <30) and Grade2 (BMI >30 kg/m2) at Gandhi Medical College, Bhopal during April to June 2019. Complete physical examination and blood tests including fasting blood glucose and oral glucose tolerance test (OGTT) were done.Results: Results shows that 16% male and 14% female subjects had IGT. Male of age more than 60yrs and female aged between 51 to 60 were more pre-diabetic. Males having weight 71 to 80 kg and female of 51-60 kg were more pre-diabetic. Subjects with grade 1 obesity, 6.12% male and 5.88% female had IGT. Similarly, in grade 2-obese subjects 10.20% males and 7.84% females had IGT.Conclusion: IGT is more prevalent in grade-1 and grade-2 obese population and a strong indicator of diabetes.

Cinammon (Cinnamomum Spp.) and Type 2 Diabetes Mellitus

2019 ◽  
Vol 18 (3) ◽  
pp. 247-255
Author(s):  
Sierra-Puente D. ◽  
Abadi-Alfie S. ◽  
Arakanchi-Altaled K. ◽  
Bogard-Brondo M. ◽  
García-Lascurain M. ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Systematic Reviews ◽  
Meta Analysis ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Key Aspects

Spices such as cinnamon (Cinnamomum Spp.) have been of interest due to their phytochemical composition that exert hypoglycemic effects with potential for management of type 2 diabetes mellitus (T2DM). We summarize data from 27 manuscripts that include, one book chapter, 3 review articles, 10 randomized controlled trials, 4 systematic reviews with meta-analysis, and 9 preclinical studies. The most frequently used cinnamon variety was Cinnamomum cassia rather than the Cinnamomum zeylanicum, whereas outcomes were defined as fasting blood glucose, glycated hemoglobin, and oral glucose tolerance test. A great variability in methodology such as different doses (from 120 mg to 6 g), duration of intervention, data retrieved and use of different concomitant medication, were found to be key aspects of most of trials and systematic reviews with meta-analysis available to date. Low quality studies have been made in most cases with a lot of heterogeneity clouding significance of results. More research needs to be done in order to yield accurate evidence for evidence-based recommendations. Its use is not currently a reliable nor advisable option for the treatment of T2DM.

scholarly journals Pre-impaired Fasting Glucose State Is A Risk Factr for Endothelial Dysfunction Flow-mediated Dilation Japan (FMD-J) Study

2020 ◽  
Author(s):  
Takayuki Yamaji ◽  
Takahiro Harada ◽  
Yu Hashimoto ◽  
Yuji Takaeko ◽  
Masato Kajikawa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Endothelial Dysfunction ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Fasting Blood Glucose ◽  
Large Sample Size ◽  
Clinical Trial Registry ◽  
Significant Difference

Abstract Background There is little information on the relationships of fasting blood glucose (FBG) including high normal blood glucose and impaired fasting glucose (IFG) with endothelial function. The purpose of this study was to evaluate the relationship between FBG level and flow-mediated vasodilation (FMD) in detail using a large sample size. Methods This study was a cross-sectional study. We measured FMD in 7265 subjects at 31 general hospitals. The subjects were divided into four groups based on FBG levels: <5.55 mmol/L, 5.55–6.05 mmol/L, 6.11–6.94 mmol/L, and ≥ 6.99 mmol/L or known type 2 diabetes. The subjects were also divided into six groups based on FBG levels: <5.00 mmol/L, 5.00-5.22 mmol/L, 5.27–5.50 mmol/L, 5.55–6.05 mmol/L, 6.11–6.94 mmol/L, and ≥ 6.99 mmol/L or known type 2 diabetes. Results FMD decreased in relation to increase in FBG level. There was a significant difference in FMD between the FBG of < 5.55 mmol/L group and the other three groups (6.7 ± 3.1% vs. 5.9 ± 2.8%, 5.7 ± 3.1%, and 5.1 ± 2.6%; p < 0.001, respectively). After adjustment for confounding factors, the odds of having the lowest quartile of FMD was significantly higher in the FBG of 5.27–5.50 mmol/L, 5.55–6.05 mmol/L, 6.11–6.94 mmol/L, and ≥ 6.99 mmol/L or known type 2 diabetes groups than in the FBG of < 5.00 mmol/L, group. Conclusions These findings suggest that FBG of 5.55–6.05 mmol/L and FBG of 6.11–6.94 mmol/L are similarly associated with endothelial dysfunction and that a pre-IFG state (FBG of 5.27–5.50 mmol/L) is also a risk for endothelial dysfunction compared with FBG of < 5.00 mmol/L. Clinical Trial Registry Information: http://www.umin.ac.jp (UMIN000012950, UMIN000012951, UMIN000012952, and UMIN000003409)

A CROSS-SECTIONAL STUDY OF THE ASSOCIATION BETWEEN THE 1-HOUR ORAL GLUCOSE TOLERANCE TEST AND THE METABOLIC SYNDROME IN A HIGH-RISK SAMPLE WITH IMPAIRED FASTING GLUCOSE

2020 ◽  
Vol 26 (5) ◽  
pp. 529-534
Author(s):  
Juan Carlos Lizarzaburu-Robles ◽  
Lizardo Torres-Aparcana ◽  
Raúl Mansilla ◽  
José Valera ◽  
Gabriela Vargas ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Glucose Tolerance ◽  
Oral Glucose Tolerance Test ◽  
Impaired Fasting Glucose ◽  
Glucose Tolerance Test ◽  
Fasting Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Glucose Levels

Objective: The aim of this study was to evaluate the association between the 1-hour oral glucose tolerance test (OGTT) (≥155 mg/dL) and metabolic syndrome (MS) in a sample with previous impaired fasting glucose (IFG). Methods: Three hundred and twenty four Peruvian subjects with a history of IFG ≥100 mg/dL were selected for a cross-sectional study. They underwent a 75 g OGTT and were assigned to different groups according to the result. We evaluated the association between 1-hour OGTT and MS. Results: The mean age was 56.5 ± 12.6 years and 191 (61.5%) were female. During the OGTT, we found 28 (8.6%) subjects with diabetes, 74 (22.8%) with IGT, and 222 (68.5%) with a normal glucose tolerance test with a 2-hour glucose <140 mg/dL (NGT). In the NGT group, 124 (38.3%) had 1-hour glucose levels <155 mg/dL, while 98 (30.2%) had 1-hour glucose levels ≥155 mg/dL. Evaluating the association between the 1-hour value in the OGTT and MS, we found that subjects with a 1-hour glucose ≥155 mg/dL were more than twice as likely to have MS as those with a 1-hour glucose <155 mg/dL (odds ratio = 2.64, 95% confidence interval: 1.52 to 4.57). In addition, body mass index, fasting glycemia, triglycerides, and waist circumferences were significantly higher in subjects with 1-hour glucose levels ≥155 mg/dL compared to those with 1-hour glucose levels <155 mg/dL ( P<.05). Conclusion: Among subjects with IFG, performing an OGTT was helpful to identify subjects with 1-hour glucose levels ≥155 mg/dL and NGT who were significantly more likely to have MS and a worse cardiometabolic risk profile. Abbreviations: AST = aspartate aminotransferase; BMI = body mass index; CI = confidence interval; IFG = impaired fasting glucose; IGT = impaired glucose tolerance; LDL = low-density lipoprotein; MS = metabolic syndrome; NGT = normal glucose tolerance; OGTT = oral glucose tolerance test; OR = odds ratio; T2DM = type 2 diabetes; TG = triglycerides

scholarly journals Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control

2009 ◽  
Vol 161 (1) ◽  
pp. 57-64 ◽  
Author(s):  
Steen B Haugaard ◽  
Huiling Mu ◽  
Allan Vaag ◽  
Sten Madsbad
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Body Fat ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Vastus Lateralis ◽  
Obese Women ◽  
Triglyceride Content ◽  
Obese Subjects

ObjectiveIt remains unknown whether sex impacts on intramyocellular triglyceride (IMTG) in obesity, as has been shown in non-obese subjects, and, if so, whether this may have implications on the association between IMTG and insulin sensitivity.Subject and methodsA muscle biopsy from vastus lateralis was obtained in 27 obese women (body mass index (BMI)=35.5±0.8 kg/m2; mean±s.e.m., percentage of body fat (PBF)=44±1, n=7  impaired fasting glucose, n=7 type 2 diabetes), 20 obese men (BMI=35.8±0.8 kg/m2; PBF=33±1, n=4 impaired-fasting-glucose; n=6 type 2 diabetes) and 12 lean sedentary healthy individuals (controls; n=7 women, BMI=21.8±0.7 kg/m2, PBF=20±2; n=5 men, BMI=23.6±0.5 kg/m2, PBF=13±2). IMTG was determined by chromatography.ResultsIMTG was increased twofold in obese women compared to obese men, lean men and lean women respectively (21.9±2.4 mg/g wet weight, 10.9±1.5, 9.8±2.1 and 10.9±2.4 mg/g, P<0.001). Among obese subjects of either gender IMTG did not increase along with reduced glycaemic control in terms of impaired fasting glucose and diabetes. Plasma insulin levels, which were similar among obese women with different glycaemic control levels, but much lower in lean women, paralleled the changes in IMTG among women. PBF was associated with IMTG in all subjects (P<0.001). In a linear model, sex (P<0.05) and PBF (P<0.05) independently explained variation in IMTG. Plasma free fatty acids (FFA) correlated with IMTG in all subjects (P<0.005).ConclusionObese women display twice as much IMTG as obese men matched for BMI. Increased IMTG could be a pathophysiological element or a mere physiological phenomenon in feminine obesity ensuing prior to impaired glycaemic control, but associated with increased body fat, circulating FFA and insulin.

scholarly journals Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: an overview of the data from the epidemiological studies within the IMI DIRECT Consortium

2018 ◽  
Author(s):  
Robert W. Koivula ◽  
Ian M. Forgie ◽  
Azra Kurbasic ◽  
Ana Viñuela ◽  
Alison Heggie ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Fasting Glucose ◽  
Tolerance Test ◽  
Glucose Regulation ◽  
Oral Glucose ◽  
Diabetes Research ◽  
Normal Glucose

Abstract/SummaryBackground and aims:Understanding the aetiology, clinical presentation and prognosis of type 2 diabetes (T2D) and optimizing its treatment might be facilitated by biomarkers that help predict a person’s susceptibility to the risk factors that cause diabetes or its complications, or response to treatment. The IMI DIRECT (Diabetes Research on Patient Stratification) Study is a European Union (EU) Innovative Medicines Initiative (IMI) project that seeks to test these hypotheses in two recently established epidemiological cohorts. Here, we describe the characteristics of these cohorts at baseline and at the first main follow-up examination (18-months).Materials and methods:From a sampling-frame of 24,682 European-ancestry adults in whom detailed health information was available, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm and enrolled into a prospective cohort study (n=2127) undertaken at four study centres across Europe (Cohort 1: prediabetes). We also recruited people from clinical registries with recently diagnosed T2D (n=789) into a second cohort study (Cohort 2: diabetes). The two cohorts were studied in parallel with matched protocols. Endogenous insulin secretion and insulin sensitivity were modelled from frequently sampled 75g oral glucose tolerance (OGTT) in Cohort 1 and with mixed-meal tolerance tests (MMTT) in Cohort 2. Additional metabolic biochemistry was determined using blood samples taken when fasted and during the tolerance tests. Body composition was assessed using MRI and lifestyle measures through self-report and objective methods.Results:Using ADA-2011 glycaemic categories, 33% (n=693) of Cohort 1 (prediabetes) had normal glucose regulation (NGR), and 67% (n=1419) had impaired glucose regulation (IGR). 76% of the cohort was male, age=62(6.2) years; BMI=27.9(4.0) kg/m2; fasting glucose=5.7(0.6) mmol/l; 2-hr glucose=5.9(1.6) mmol/l [mean(SD)]. At follow-up, 18.6(1.4) months after baseline, fasting glucose=5.8(0.6) mmol/l; 2-hr OGTT glucose=6.1(1.7) mmol/l [mean(SD)]. In Cohort 2 (diabetes): 65% (n=508) were lifestyle treated (LS) and 35% (n=271) were lifestyle + metformin treated (LS+MET). 58% of the cohort was male, age=62(8.1) years; BMI=30.5(5.0) kg/m2; fasting glucose=7.2(1.4)mmol/l; 2-hr glucose=8.6(2.8) mmol/l [mean(SD)]. At follow-up, 18.2(0.6) months after baseline, fasting glucose=7.8(1.8) mmol/l; 2-hr MMTT glucose=9.5(3.3) mmol/l [mean(SD)].Conclusion:The epidemiological IMI DIRECT cohorts are the most intensely characterised prospective studies of glycaemic deterioration to date. Data from these cohorts help illustrate the heterogeneous characteristics of people at risk of or with T2D, highlighting the rationale for biomarker stratification of the disease - the primary objective of the IMI DIRECT consortium.Abbreviations:ASATAbdominal subcutaneous adipose tissueDIRECTDiabetes Research on Patient StratificationEUEuropean UnionMMTTMixed-meal tolerance testMRIMagnetic resonance imaginghpfVMHigh-pass filtered vector magnitudeIAATIntra-abdominal adipose tissueIGRImpaired glucose regulationIMIInnovative Medicines InitiativeMEmultiechoNGRNormal glucose regulationOGTTOral glucose tolerance testPAPhysical activityTAATTotal abdominal adipose tissueT2DType 2 Diabetes

Sign in / Sign up

Export Citation Format

Share Document